Our subject experts have strong connections with NHS England, to understand upcoming requirements. We have experience of implementing enabling technology and, as the largest CSU, we have contacts across multiple healthcare communities to understand a range of practical solutions.
Our senior pharmacists provide strategic input to nationally recognised groups for policy consideration and are members of the General Pharmaceutical Council and the Royal Pharmaceutical Society.
Our team are recognised authorities on Payment by Results exempt (PbRe) drugs and the complexity of prescribing them. We promote effective dialogue with CCGs to understand the impact of their plans on cost and demand. We help benchmark, forecast the cost and review the use of PbRes. We use the provider’s criteria for the Blueteq approval process to quantify the cost, monitor this through our medicines optimisation dashboard and use NICE innovation scorecards.